Abstract
Serum concentrations of fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) are elevated in patients with CKD, and higher concentrations are well established as risk factors for cardiovascular disease and death ([1][1]). In the Systolic Blood Pressure Intervention Trial (SPRINT),
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical journal of the American Society of Nephrology : CJASN
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
